Q3 EPS Estimate for Axsome Therapeutics Reduced by Analyst

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Equities researchers at Zacks Research dropped their Q3 2026 earnings estimates for shares of Axsome Therapeutics in a note issued to investors on Thursday, January 16th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $0.04 for the quarter, down from their previous forecast of $0.11. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($4.61) per share.

A number of other research firms have also commented on AXSM. Royal Bank of Canada raised their price target on Axsome Therapeutics from $130.00 to $131.00 and gave the stock an “outperform” rating in a research report on Friday, October 4th. Truist Financial raised their target price on shares of Axsome Therapeutics from $150.00 to $180.00 and gave the stock a “buy” rating in a report on Monday, January 13th. StockNews.com upgraded shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Mizuho dropped their price objective on shares of Axsome Therapeutics from $124.00 to $122.00 and set an “outperform” rating on the stock in a report on Tuesday, December 31st. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $133.00 target price on shares of Axsome Therapeutics in a research note on Monday, January 13th. One analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $130.69.

Axsome Therapeutics Stock Performance

AXSM stock opened at $91.93 on Monday. Axsome Therapeutics has a 1-year low of $64.11 and a 1-year high of $105.00. The company has a current ratio of 2.44, a quick ratio of 2.37 and a debt-to-equity ratio of 1.97. The firm has a market cap of $4.45 billion, a PE ratio of -14.08 and a beta of 1.04. The business’s 50-day moving average price is $92.27 and its two-hundred day moving average price is $89.53.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.38) by $0.04. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. The company had revenue of $104.76 million for the quarter, compared to analysts’ expectations of $98.71 million. During the same period last year, the firm posted ($1.32) earnings per share.

Institutional Trading of Axsome Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Northwestern Mutual Wealth Management Co. acquired a new position in Axsome Therapeutics during the second quarter valued at approximately $27,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Axsome Therapeutics in the 2nd quarter valued at approximately $47,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Axsome Therapeutics by 22.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock valued at $156,000 after buying an additional 318 shares in the last quarter. Moors & Cabot Inc. bought a new position in shares of Axsome Therapeutics in the third quarter valued at $200,000. Finally, Whalen Wealth Management Inc. acquired a new position in Axsome Therapeutics during the third quarter worth $236,000. Institutional investors and hedge funds own 81.49% of the company’s stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.